Glenmark is the first company to launch in India a Triple FDC of Teneligliptin + Pioglitazone + Metformin  for Adults with Type 2 Diabetes & High Insulin Resistance


PUNE, 25 December 2022  : Glenmark Pharmaceuticals Limited (Glenmark), an innovation-driven, global pharmaceutical company has launched the first triple fixed-dose combination Teneligliptin with Pioglitazone and Metformin in India. Teneligliptin is a widely used DPP4 inhibitor (Dipeptidyl Peptidase 4 inhibitor). This FDC has been launched under the brand name Zita®-PioMet, and contains Teneligliptin (20 mg) + Pioglitazone (15 mg) + Metformin (500mg/1000mg) in a sustained release (SR) formulation. This offers patients with Type 2 diabetes the convenience of once daily dosing to improve their glycemic control and achieve the targeted HbA1c within 24 weeks. 

  •         This Fixed-Dose Combination (FDC) of Teneligliptin (20 mg) + Pioglitazone (15 mg) + Metformin (500mg/1000mg) SR under the brand name Zita®-PioMet.
  •         The novel triple FDC will help improve glycemic control among adults with High HbA1c[i] and high insulin resistance, those whose diabetes is uncontrolled by metformin alone; and those who require the addition of Teneligliptin and Pioglitazone as separate drugs; thus improving adherence with single pill. 
  •         Priced at Rs. 14.90 per day, it will reduce the daily cost of therapy by 40%, making it more affordable to the masses.

On occasion of the launch, Alok Malik, EVP & Business Head ‐ India Formulations, Glenmark Pharmaceuticals Ltd., said, “Type 2 diabetes patients in India often face issues of beta cell dysfunction along with insulin resistance. In fact, the prevalence of high insulin resistance in India is 38% compared to the global incidence of 15%ii. Being a leader in diabetes therapy in the country, we are proud to introduce Zita®-PioMet, India’s first triple fixed dose combination for high insulin-resistant type 2 diabetes. The innovative, effective, and affordable drug will help improve the glycemic control among adult patients with high HbA1c.”

Glenmark’s Leadership in the Diabetes Segment

Glenmark has a strong legacy of bringing in new, effective and affordable treatment options for diabetic patients, especially the ones with uncontrolled Type 2 diabetes. In 2015, Glenmark was the first to launch the DPP4 inhibitor, Teneligliptin (Zita Plus® and Ziten®), followed by a FDC of Teneligliptin + Metformin (Zita-Met Plus® and Ziten-M®). Glenmark later launched Remogliflozin (Remo® and Remozen™), a novel SGLT‐2 inhibitor in 2019 and subsequently, its combinations with Metformin and Vildagliptin (Remo-V®, Remozen™-V, Remo MV® and Remozen™ MV). Earlier in 2022, Glenmark also launched Sitagliptin (Sitazit®) and its FDCs, followed by Lobeglitazone (LOBG®) and FDCs of Teneligliptin including its combinations with Pioglitazone (Zita Pio™) and Dapagliflozin (Zita-D™).

Diabetes in India: According to IQVIA™ sales data for the 12‐month period ending November 2022, the market for oral anti‐diabetic drugs in India is estimated to be Rs. 11,877 Cr. with an annual growth of 6.3% against the corresponding period last year (MAT November 2021). As per the International Diabetes Federation (IDF), the prevalence of diabetes in India is expected to increase to 125 million by 2045, 77% of which would have uncontrolled diabetes.